Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include ...

First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or ...